Abstract
Hypoxia-associated proteome changes have been shown to be associated with resistance to chemo- and radiotherapy. Our study evaluated the role of the hypoxia-inducible (HIF)-1 target gene carbonic anhydrase (CA) IX in the prediction of the response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer (stages II and III). A total of 29 pretreatment biopsy specimens were stained for CA IX by immunohistochemistry, converted to digital images and evaluated in a quantitative fashion using image analysis software. Contrary to our expectations, a trend towards a correlation between better tumor regression (>50 %) and higher expression of CA IX (p = 0.056) was found. CA IX was also present more frequently in pathological tumor stage T1 (pT1) tumors (p = 0.048). Conversely, no association with lymph node metastasis was identified. In conclusion, as a single marker, CA IX expression is not able to identify a hypoxia-related treatment resistant phenotype in rectal cancer.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sauer R, Becker H, Hohenberger W et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740
Bosset J-F, Collette L, Calais G et al (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355(11):1114–1123
Gerard J-P, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24(28):4620–4625
Fokas E, Liersch T, Fietkau R et al (2014) Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial. J Clin Oncol 32(15):1554–1562
Habr-Gama A, Sabbaga J, Gama-Rodrigues J et al (2013) Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 56(10):1109–1117
Maas M, Beets-Tan RGH, Lambregts DMJ et al (2011) Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol 29(35):4633–4640
Semenza GL (2012) Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 33(4):207–214
Mayer A, Vaupel P (2011) Hypoxia markers and their clinical relevance. In: Osinsky S, Friess H, Vaupel P (eds) Tumor hypoxia in the clinical setting. Akademperiodyka, Kiev, pp 187–202
Guedj N, Bretagnol F, Rautou PE et al (2011) Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Hum Pathol 42(11):1702–1709
Potter CP, Harris AL (2003) Diagnostic, prognostic and therapeutic implications of carbonic anhydrases in cancer. Br J Cancer 89(1):2–7
Ojugo AS, McSheehy PM, Stubbs M et al (1998) Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells. Br J Cancer 77(6):873–879
Rasheed S, Harris AL, Tekkis PP et al (2009) Assessment of microvessel density and carbonic anhydrase-9 (CA-9) expression in rectal cancer. Pathol Res Pract 205(1):1–9
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media, New York
About this paper
Cite this paper
Mayer, A. et al. (2016). Hypoxia-Associated Marker CA IX Does Not Predict the Response of Locally Advanced Rectal Cancers to Neoadjuvant Chemoradiotherapy. In: Elwell, C.E., Leung, T.S., Harrison, D.K. (eds) Oxygen Transport to Tissue XXXVII. Advances in Experimental Medicine and Biology, vol 876. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-3023-4_24
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3023-4_24
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-3022-7
Online ISBN: 978-1-4939-3023-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)